HIGHMARK WHOLECARE

Updated: 10/2025
Approved:12/2025

Prior Authorization Criteria

Gattex (teduglutide)

All requests for Gattex (teduglutide) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a diagnosis of short bowel syndrome (SBS) and the following criteria is met:

- The member must be 1 year of age or older
- Must be prescribed by or in consultation with a gastroenterologist
- Documentation the member has a history of being dependent on parenteral support
- Documentation the following has occurred within 6 months prior to initiating Gattex (teduglutide):
    - Members 18 and older: a colonoscopy and an upper gastrointestinal (GI) endoscopy performed and polyps have been removed
    - Members under 18: a fecal occult blood test has been performed and if there was unexplained blood in the stool a colonoscopy/sigmoidoscopy and an upper gastrointestinal (GI) endoscopy has been performed
- Documentation of baseline PN/IV frequency and volume
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 6 months
- **Reauthorization criteria:**
    - Documentation of at least one of the following
        - The member has at least a 20% reduction in weekly PN/IV volume from baseline
        - The member has achieved enteral autonomy
        - The member has had a reduction in parenteral support infusion of ≥1 day per week
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

HIGHMARK WHOLECARE

Updated: 10/2025
Approved:12/2025

GATTEX (TEDUGLUTIDE)
PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Wholecare Pharmacy Services. **FAX:** (888) 245-2049
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (800) 392-1147 Mon – Fri 8:30am to 5:00pm

PROVIDER INFORMATION

Requesting Provider:	Provider NPI:
Provider Specialty:	Office Contact:
State license #:	Office NPI:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? ☐ Yes ☐ No	Date Medication Initiated:	

Billing Information

This medication will be billed: ☐ at a pharmacy **OR** ☐ medically, JCODE:_____

Place of Service: ☐ Hospital ☐ Provider's office ☐ Member's home ☐ Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis:	ICD Code:

Please mark one of the following:

- The member is 18 or older and has had a colonoscopy and an upper gastrointestinal (GI) endoscopy (within 6 months) and polyps have been removed (if applicable)
  ☐ Yes ☐ No
- The member is under 18 and has had a fecal occult blood test (within 6 months) and if there was unexplained blood in the stool a colonoscopy/sigmoidoscopy and an upper gastrointestinal (GI) endoscopy has been performed ☐ Yes ☐ No
- Is the member dependent on parenteral support? ☐ Yes ☐ No

Please provide the member's baseline parenteral nutrition/IV fluid usage. (Please include both frequency and volume): _____

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

REAUTHORIZATION

Please provide the member's baseline parenteral nutrition/IV fluid usage. (Please include both frequency and volume): _____

Please provide the member's current parenteral nutrition/IV fluid usage. (Please include both frequency and volume):_____

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature Date
